Editorial

Tempering the risk: Rift Valley fever and bioterrorism

Osman Dar1, Sue Hogarth2 and Sabrina McIntyre2

1 Centre on Global Health Security, Chatham House, London, UK
2 Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK

keywords Rift Valley fever, bioterrorism, research, biosecurity, global health

Rift Valley fever virus (RVFV) is an arthropod-borne pathogen that primarily affects ruminants in eastern and sub-Saharan Africa first described following an outbreak on a farm in Kenya in 1931. Periodic outbreaks of RVFV since that time have resulted in significant losses to the African livestock industry as well as large numbers of infections in some of the most impoverished human populations. In one 2006/2007 outbreak across Kenya, Somalia and Tanzania alone, there were an estimated 145,000 human cases, and the ban imposed on imports after the 1997/1998 outbreak in Somalia led to a collapse of the vital livestock industry. Previously ignored, it is only in the past decade that the international community has started to take an increased interest in the disease. This followed the recognition of its potential to spread beyond the confines of the African continent after a large outbreak in Saudi Arabia in 2000. There has also been acknowledgement of the widespread presence of arthropod vectors capable of transmitting RVFV in many non-endemic regions of the world. This has led to a range of increased efforts in better understanding the virus and developing tools to predict outbreaks, combat the disease and limit its spread (Anyamba et al. 2010; Pepin et al. 2010).

However, a more longstanding, parallel interest in the disease has also developed internationally; one centred around the biosecurity implications of the virus. The United States for instance, included RVFV as a candidate pathogen in its offensive biological weapons programme; a programme officially closed in 1969 (Borio et al. 2002). In more recent times, the classification of the virus as a potential bioterrorism agent has spurred investment and activity, particularly in the area of vaccine development and diagnostics (Borio et al. 2002; Sidwell & Smee 2003).

While biosecurity interest has contributed to this increased funding over the past few decades, most notably from military sources such as the US Army Medical Research Institute of Infectious Diseases (USAMRIID), it may have acted as an impediment to international collaboration, with research being restricted to fewer, more expensive laboratories. After the signing of the US Patriot Act of 2002 and the classification of RVFV as a ‘select agent’, visiting experts and scientific collaborators are, for instance, now required to provide fingerprints, signed affidavits and be registered with intelligence services before working with the pathogen. Such measures are likely to act as a disincentive amongst scientists wanting to study the virus and could ultimately serve to drive experts to dedicate their efforts to other pathogens with fewer working restrictions (Animal & Plant Health Inspection Service, Centre for Disease Control & Prevention 2005, 2011). These restrictions have also been applied in parts of Europe as well, with national legislation such as the Anti-terrorism, Crime and Security Act 2001 of the UK, which also includes RVFV as a potential bioterrorism agent. For comparison and contrast, we include the current lists of biological agents and toxins around which bioterrorism legislation has been passed in the US and UK in Table 1.

Focus on US policy internationally stems from its greater leadership role within the global community and the influence and impact its decisions have on people and institutions far beyond its borders. With large numbers of laboratories worldwide affected by US policy either directly through funding or indirectly as a result of political influence, restrictions have also resulted in the transfer between laboratories of RVFV samples for culture also becoming constrained and increasingly expensive. This undermines efforts to lower the industrial production costs of existing vaccines and of commercial kits for virus neutralisation and ELISA diagnostic tests (currently the prescribed tests for international livestock trade) (World Organization for Animal Health 2008). Expertise and experience thus tends to remain confined to a limited number of laboratories and companies by and large located in high income countries where investigation of the disease is neither a significant economic or health priority nor considered sufficiently profitable for drug companies. The resulting monopolies on expert technical knowledge and skills not only delays progress in developing new therapies.
| Biological agents and toxins (US and UK Governments) |
|---------------------------------------------------|
| **US (National Select Agent Registry 2012)** | **UK (HMSO 2001)** |
| **Abrin** | Chikungunya virus |
| Botulinum neurotoxins* | Congo-crimewa haemorrhagx fever virus |
| Botulinum neurotoxin producing species of *Clostridium* | Dengue fever virus |
| Conotoxins (Short, paralytic alpha conotoxins containing the following amino acid sequence $X_1CCX_2PACGX_3X_4X_5X_6CX_7$) | Ebola virus |
| *Coxiella burnetii* | Everglades virus |
| Crimean-Congo haemorrhagx fever virus | Geta virus |
| *Diacetoxyscirpenol* | Guanant virus |
| Eastern eunie encephalitis virus† | Hantaan virus |
| *Ebola virus* | Hendra virus (Equine morbillivirus) |
| *Francisella tularensis* | Herpes simae (B virus) |
| Lassa fever virus | Influenza viruses (pandemic strains) |
| Lujo virus | Japanese encephalitis virus |
| Marburg virus* | Junin virus |
| Monkeypox virus† | Kyasanur Forest virus |
| Reconstructed replication competent forms of the 1918 pandemic influenza virus containing any portion of the coding regions of all eight gene segments (Reconstructed 1918 Influenza virus) | Lassa fever virus |
| *Ricin* | Louping ill virus |
| *Rickettsia prowazekii* | Lympohocytic choriomeingeitis virus |
| SARS-associated coronavirus (SARS-CoV) | Machupo virus |
| Saxitoxin | Marburg virus |
| South American Haemorrhagx Fever viruses: | Maya virus |
| *Chapare* | Middleburg virus |
| Guanarito | Mohala virus |
| Junin | Monkey pox virus |
| Machupo | Mucambo virus |
| *Saba* | Murray Valley encephalitis virus |
| Staphylococcal enterotoxins A, B, C, D, E subtypes | Nipah virus |
| T-2 toxin | Noma virus |
| Tetrodotoxin | Omik haemorrhagx fever virus |
| Tick-borne encephalitis complex (llavi) viruses: | Polio virus |
| Far Eastern subtype | Powassan virus |
| Siberian subtype | Rabies virus |
| Kyasanur Forest disease virus | Rift Valley fever virus |
| *Omik haemorrhagx fever virus* | Rocio virus |
| *Variola major virus* (Smallpox virus)* | Sabia virus |
| *Variola minor virus* (Alastrim)* | Sagiyama virus |
| *Yersinia pestis* | Sin Nombre virus |
| | St Louis encephalitis virus |
| | Tick-borne encephalitis virus (Russian Spring-Summer encephalitis virus) |
| US (National Select Agent Registry 2012) | UK (HMSO 2001) |
|----------------------------------------|-----------------|
| US Department of Agriculture (USDA) select agents and toxins | | |
| US Department of Agriculture (USDA) select agents and toxins | | |
| African horse sickness virus | | |
| African swine fever virus | | |
| Avian influenza virus | | |
| Classical swine fever virus | | |
| Foot-and-mouth disease virus | | |
| Goat pox virus | | |
| Lumpy skin disease virus | | |
| Mycoplasma capricolum | | |
| Mycoplasma mycoides | | |
| Newcastle disease virus | | |
| Peste des petits ruminants virus | | |
| Rinderpest virus | | |
| Sheep pox virus | | |
| Swine vesicular disease virus | | |
| US Department of Agriculture (USDA) select agents and toxins | | |
| Peronosclerospora philippinensis (Peronosclerospora sacchari) | | |
| Phoma glycinicola (formerly Pyrenochaeta glycines) | | |
| Ralstonia solanacearum | | |
| Rathayibacter toxicus | | |
| Sclerophthora rayssiae | | |
| Synchytrium endobioticum | | |
| Xanthomonas oryzae | | |

**Table 1 (continued)**

† Select agents that meet any of the following criteria are excluded from the requirements of this part: Any low pathogenic strains of avian influenza virus, South American genotype of eastern equine encephalitis virus, any strain of Newcastle disease virus which does not meet the criteria for virulent Newcastle disease virus, all subspecies Mycoplasma capricolum except subspecies capripneumoniae (contagious caprine pleuropneumonia), all subspecies Mycoplasma mycoides except subspecies Mycoplasma mycoides small colony (Mmm SC) (contagious bovine pleuropneumonia), any subtype of Venezuelan equine encephalitis virus except for the IAB or IC and vesicular stomatitis virus (VSV) IN subtype (Indiana subtype of VSV) since 1988, and any strain of Newcastle disease virus (avian paramyxovirus type 1) has an intracerebral pathogenicity index in day-old chicks (Gallus gallus) of 0.7 or greater or has an amino acid sequence at the fusion (F) protein cleavage site that is consistent with virulent strains of Newcastle disease virus. A failure to detect a cleavage site that is consistent with virulent strains does not confirm the absence of a virulent virus.

‡ A virulent Newcastle disease virus (avian paramyxovirus type 1) has an intracerebral pathogenicity index in day-old chicks (Gallus gallus) of 0.7 or greater or has an amino acid sequence at the fusion (F) protein cleavage site that is consistent with virulent strains of Newcastle disease virus. A failure to detect a cleavage site that is consistent with virulent strains does not confirm the absence of a virulent virus.
Box 1: US CDC and NIAID categorisation of bioterrorism agents and biodefense priority pathogens.

Category A pathogens are those organisms/biological agents that pose the highest risk to national security and public health because they
- Can be easily disseminated or transmitted from person to person;
- Result in high mortality rates and have the potential for major public health impact;
- Might cause public panic and social disruption; and
- Require special action for public health preparedness.

Category B pathogens are the second highest priority organisms/biological agents. They:
- Are moderately easy to disseminate;
- Result in moderate morbidity rates and low mortality rates; and
- Require specific enhancements for diagnostic capacity and enhanced disease surveillance.

Category C pathogens are the third highest priority and include emerging pathogens that could be engineered for mass dissemination in the future because of:
- Availability;
- Ease of production and dissemination; and
- Potential for high morbidity and mortality rates and major health impact.

Box 2: An excerpt from the proceedings of the ‘Responding to the Consequences of Chemical and Biological Terrorism,’ joint seminar held between the US Department of Health and Human Services, US Public Health Service (PHS) and the Office of Emergency Preparedness (OEP) in July 1995.

“If I wanted to disrupt the Middle East peace process between Israel and the PLO, I would infect one small, young lamb with Rift Valley fever virus. I would hold that lamb in a confined area for about 48 hours; at that point in time the lamb is very sick. I bleed 200 milliliters from his heart; I keep that blood from clotting by means of heparin. If the heparin is not available to me, I have picked up some small stones, and I have sterilized them in boiling water. I add those stones to the fluid, and I shake it up, and I prevent clotting. Then I harvest the lung and the liver and get 600 milliliters of blood and organs. I add 5,400 milliliters of a 5-percent skim milk solution, homogenize again in a Waring blender, filter, filter, filter. I filter it through several layers of gauze, and I get 5,900 milliliters containing $1 \times 10^{10}$, 10,000,000,000 units of virus. Using my old pal Calder's mathematical model, if I disseminate that as a line source, perpendicular to the wind, 2 milliliters per meter, and I walk along for 2,950 meters, I will infect 50 percent of the population 0.4 of a kilometer downwind; 30 percent of the population at 1.5 kilometers downwind; and 10 percent of the population 3 kilometers downwind. I have hedged here. I have used very good meteorological conditions. The ridge height, or course I am walking along spraying, is zero feet. The transport wind is 5 miles per hour, which is very good for transport of a BW agent. Your diffusion parameter is $n = 0.4$, the beta factor is 0.8, and I have selected deliberately to bias the thing in my favor, a stability condition of a very strong inversion (US Department of Health & Human Services USPHS, Office of Emergency Preparedness 1995).”

While aerosolised droplet transmission of the virus is clearly possible, with notable recorded transmissions occurring in abattoir and laboratory workers from infected animal specimens and parts, this is not a unique feature amongst a plethora of infectious diseases. RVFV with its low mortality and relatively low human-to-
human transmissibility in comparison with other viral haemorrhagic fever (VHF) viruses such as Ebola, Marburg or Lassa, should have its risk profile assessed independently. As such, while the US Centre for Disease Control (CDC) has indeed categorised VHF viruses as category A bioterrorism agents (Box 1); it specifically refers to filoviruses (e.g. Ebola and Marburg) and arenaviruses (e.g. Lassa) in this regard, and RVFV does not appear at all in its list of potential bioterrorism agents (Centre for Disease Control & Prevention 2012). Expert commissions have, however, at times tended to band all VHFs together, resulting in legislation that has overplayed the specific risk of RVFV to human health (Borio et al. 2002). For instance, the US National Institute of Allergy and Infectious Diseases, using the same categorisation as the CDC, includes RVFV specifically as a category A agent thus incorrectly implying high pathogenicity and high human-to-human transmissibility (National Institute of Allergy & Infectious Diseases 2011).

While it is not inconceivable that a variety of state and non-state actors may attempt to develop RVFV as a biological weapon, its large scale effectiveness seems limited to causing economic damage through the deliberate infection of livestock (Borio et al. 2002). In the event that the virus was selected for development as a bioterrorism agent, the current wide ranging restrictions placed on legitimate scientists and vaccine/diagnostic kit manufacturers working with the virus are unlikely to act as a significant deterrent to entities determined to obtain live RVFV samples for culture and study. With the virus so widespread in so many parts of Africa, obtaining live samples from an array of vertebrate hosts and culturing it thereafter is a relatively simple process (Box 2) (US Department of Health & Human Services USPHS, Office of Emergency Preparedness 1995). Such restrictions thus potentially hinder the development of necessary biological solutions for wider disease control and also provide a false sense of security.

Bunyaviruses, like RVFV, are known to be easily cultivated in vitro and can therefore be prepared in large quantities (Sidwell & Smee 2003; Pepin et al. 2010). With new advances in recombinant techniques, there may thus be a heightened sense of wariness around the potential for a more pathogenic (to humans) variant of the virus being produced by bioterrorists. For RVFV in particular, this is tempered to an extent in comparison with other bunyaviruses as it is believed to have a relatively low tolerance to genetic mutation (Pepin et al. 2010). As such, while it is important to recognise that evolving technologies mean that RVFV still poses a theoretical bioterrorism risk, it is arguably more important to recognise that the virus causes very real morbidity and mortality naturally and that this consideration should take precedence in the worldwide approach to combating the disease.

Rift Valley fever virus disease hurts some of the most impoverished communities in the developing world through both its direct health and indirect economic effects and is an infection that has suffered decades of chronic under-investment in its control. In recent years, there has been a welcome increase in interest globally in combating this disease, and these efforts should be encouraged. However, to fully benefit from this increased interest, international policies related to biosecurity concerns around the virus should be revisited and tempered. This would not only enable better, more efficient focus on pathogens that do constitute a significant biosecurity risk, but also importantly, allow the global community to accelerate the progress being made towards improving RVFV control.

References
Animal and Plant Health Inspection Service, Centre for Disease Control and Prevention (2005) National Select Agents Registry. APHIS, CDC, Available at: http://www.selectagents.gov/Select%20Agents%20and%20Toxins.html (accessed 17 May 2010).
Animal and Plant Health Inspection Service, Centre for Disease Control and Prevention (2011) FAQs Concerning Security Risk Assessments. APHIS, CDC, Available at: http://www.selectagents.gov/FAQ_SecurityRiskAssessments.html (accessed 3 March 2013).
Anyamba A, Linthicum KJ, Small J et al. (2010) Prediction, assessment of the Rift Valley fever activity in East and Southern Africa 2006–2008 and possible vector control strategies. American Journal of Tropical Medicine and Hygiene 83(Suppl. 2), 43–51.
Borio L, Inglesby T, Peters CJ et al. (2002) Hemorrhagic fever viruses as biological weapons. JAMA: The Journal of the American Medical Association 287, 2391–2403.
Centre for Disease Control and Prevention (2012) Bioterrorism Agents/Diseases. CDC, Available at: http://emergency.cdc.gov/agent/agentlist-category.asp (accessed 5 March 2013).
HMSO (2001) Anti-terrorism, Crime and Security Act 2001. Chapter 24, Section 38, SCHEDULE 5, Pathogens and toxins, VIRUSES. Available at: http://www.legislation.gov.uk/ukpga/2001/24/schedule5/text%3DDrift%20Valley%20fever
National Institute of Allergy and Infectious Diseases (2011). NIAID Category A, B, and C Priority Pathogens. NIAID, Available at: http://www.niaid.nih.gov/topics/BiodefenseRelated/BiodefensePages/CatA.aspx (accessed 27 February 2013).
National Select Agent Registry (2012) HHS and USDA Select Agents and Toxins. 7 CFR Part 331, 9 CFR Part 121, and 42
Pepin M, Bouloy M, Bird BH, Kemp A & Paweska J (2010) Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. *Veterinary Research* 41, 61.

Sedyaningsih ER, Isfandari S, Soendoro T & Supari SF (2008) Towards mutual trust, transparency and equity in virus sharing mechanism: the avian influenza case of Indonesia. *Annals of the Academy of Medicine, Singapore* 37, 482–488.

Sidwell RW & Smee DF (2003) Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. *Antiviral Research* 57, 101–111.

US Department of Health and Human Services USPHS, Office of Emergency Preparedness, editor (1995) Responding to the Consequences of Chemical and Biological Terrorism. US Department of Health and Human Services USPHS, Office of Emergency Preparedness, Bethesda, MD.

World Organization for Animal Health (2008). Rift Valley Fever. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, 6th edn. OIE, Paris, France, pp. 323–333.

Corresponding Author Osman Dar, Centre on Global Health Security, Chatham House, 10 St James Square, London SW1Y 4LE, UK. Tel.: +44 7951 140354; E-mail: osman.dar@lshtm.ac.uk